Physician profile
Yi Dong
NPI 1104245687
$1,712.04
in general payments reported to CMS, 2019-2025
31 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $99.99 · 2024: $414 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.69 |
| Education | $221.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $247.04 | 2024-2025 | |
| Seagen INC. | $163.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.36 | 2024-2025 | Lynparza, Enhertu |
| Janssen Biotech, INC. | $122.28 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Exelixis INC. | $99.99 | 2023 | |
| Incyte Corporation | $70.98 | 2024-2025 | Zynyz, Monjuvi, Jakafi |
| Array Biopharma INC | $68.51 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Genzyme Corporation | $61.02 | 2025 | |
| Merck Sharp & Dohme LLC | $54.33 | 2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $52.65 | 2024-2025 | |
| Lilly USA, LLC | $48.84 | 2024 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $47.80 | 2025 | Vanflyta, Enhertu |
| Genentech USA, INC. | $46.88 | 2025 | Polivy, Tecentriq |
| Abbvie INC. | $40.85 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $40.06 | 2024-2025 | Qinlock, Tgct |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $39.87 | 2025 | Reblozyl |
| Gilead Sciences, INC. | $39.19 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $33.99 | 2024 | Padcev |
| Glaxosmithkline, LLC. | $32.70 | 2024 | Ojjaara |
| Eisai INC. | $28.16 | 2025 | |
| Coherus Oncology, INC. | $26.90 | 2024 | |
| Pharmaessentia USA Corporation | $24.40 | 2025 | Besremi |
| Adc Therapeutics America, INC. | $24.28 | 2025 | |
| Sobi, INC | $22.26 | 2025 | |
| Karyopharm Therapeutics INC. | $22.24 | 2025 | Xpovio |
| Acrotech Biopharma INC. | $21.12 | 2024 | Beleodaq |
| Stemline Therapeutics INC. | $20.86 | 2025 | Orserdu |
| Amgen INC. | $18.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Sun Pharmaceutical Industries INC. | $16.17 | 2025 | |
| Biosense Webster, INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.